RADX (Radiopharm Theranostics) Forward P/E Multiple
The forward P/E of Radiopharm Theranostics (RADX) exhibits volatility driven by the company's reliance on international cooperation and sanction risks associated with component supplies. The value of 0.00 determines this parameter level. The company's efficiency is bolstered by its own express delivery network for short-lived isotopes. Meanwhile, ownership of unique patents in nuclear medicine creates a powerful barrier to entry for new players.
Summary analytical data breakdowns for Radiopharm Theranostics Ltd (RADX)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Radiopharm Theranostics|RADX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Radiopharm Theranostics Limited|RADX - Aggregate Debt Obligations|Debts to Book Capitalization Radiopharm Theranostics|RADX - Company Long-Term Debts|Company Short-Term Debts Radiopharm Theranostics|Quick Ratio radiopharmtheranostics.com
- financial results and valuation multiples details:
RADX - Net Financial Result|Expected Profit Radiopharm Theranostics|RADX - Market Cap to Earnings|Future Price to Earnings Radiopharm Theranostics Limited|RADX - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Radiopharm Theranostics|RADX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Radiopharm Theranostics|RADX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months radiopharmtheranostics.com|RADX - Earnings per share increase in current year|Net earnings per share growth forecast for next year Radiopharm Theranostics
- sales volume and revenue indicators:
Fundamental valuation:radiopharmtheranostics.com
The effectiveness of targeted therapy and the stability of isotope supplies determine the future cash flows of Radiopharm Theranostics (RADX), directly impacting expected earnings. By analyzing the company's forward P/E ratio, an investor compares the current share price with projected annual income, which helps identify unjustified market overheating and assess the fairness of the asset's valuation relative to its fundamental prospects.
Analysis of competing companies
Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple
